LMR Partners LLP Purchases Shares of 21,285 Illumina, Inc. (NASDAQ:ILMN)

LMR Partners LLP purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 21,285 shares of the life sciences company’s stock, valued at approximately $2,776,000.

A number of other large investors have also made changes to their positions in ILMN. Freemont Management S.A. purchased a new stake in shares of Illumina during the 3rd quarter worth approximately $1,565,000. Cetera Advisors LLC purchased a new stake in shares of Illumina during the 1st quarter worth $610,000. Weybosset Research & Management LLC boosted its holdings in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after acquiring an additional 8,650 shares in the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock worth $749,000 after acquiring an additional 4,579 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Illumina by 3.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock worth $41,748,000 after purchasing an additional 13,725 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Stephens lifted their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. StockNews.com started coverage on Illumina in a report on Thursday, August 29th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. upped their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, November 12th. Finally, Citigroup increased their price objective on Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Price Performance

ILMN opened at $130.74 on Tuesday. The firm has a 50-day moving average price of $139.82 and a 200-day moving average price of $124.35. The company has a market capitalization of $20.74 billion, a price-to-earnings ratio of -13.13 and a beta of 1.13. Illumina, Inc. has a twelve month low of $93.39 and a twelve month high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.33 EPS. Equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.